APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Insulin Glargine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Long-acting Insulin Glargine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025199 pages

Choose your research edition.

Industry ResearchLong-acting Insulin Glargine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Insulin Glargine Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Long-acting Insulin Glargine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Insulin Glargine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Insulin Glargine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Long-acting Insulin Glargine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting Insulin Glargine include Biocare, Biocon Biologics, Cipla, INFION PHARMA, KALBE PHARMA, Lupin Laboratories, Swixx Biopharma, Viatris and Wockhardt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Insulin Glargine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Insulin Glargine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Insulin Glargine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Insulin Glargine market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Insulin Glargine Segment by Company

Biocare

Biocon Biologics

Cipla

INFION PHARMA

KALBE PHARMA

Lupin Laboratories

Swixx Biopharma

Viatris

Wockhardt

Gan & Lee

Eli Lilly & Co

Sanofi

Tonghua Dongbao

United Laboratories

Long-acting Insulin Glargine Segment by Type

Vial

Prefilled

Long-acting Insulin Glargine Segment by Application

Type 2 Diabetes

Type 1 Diabetes

Long-acting Insulin Glargine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Insulin Glargine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Insulin Glargine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Insulin Glargine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Insulin Glargine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting Insulin Glargine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Long-acting Insulin Glargine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Long-acting Insulin Glargine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Long-acting Insulin Glargine Industry Trends Table 2. Long-acting Insulin Glargine Industry Drivers Table 3. Long-acting Insulin Glargine Industry Opportunities and Challenges Table 4. Long-acting Insulin Glargine Industry Restraints Table 5. Global Long-acting Insulin Glargine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Long-acting Insulin Glargine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Long-acting Insulin Glargine Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Long-acting Insulin Glargine Sales Market Share by Manufacturers Table 9. Global Long-acting Insulin Glargine Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Long-acting Insulin Glargine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Long-acting Insulin Glargine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Long-acting Insulin Glargine Manufacturers, Product Type & Application Table 13. Global Long-acting Insulin Glargine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Insulin Glargine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Vial Table 17. Major Manufacturers of Prefilled Table 18. Global Long-acting Insulin Glargine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Long-acting Insulin Glargine Sales by Type (2021-2026) & (k units) Table 20. Global Long-acting Insulin Glargine Sales by Type (2027-2032) & (k units) Table 21. Global Long-acting Insulin Glargine Sales Market Share by Type (2021-2026) Table 22. Global Long-acting Insulin Glargine Sales Market Share by Type (2027-2032) Table 23. Global Long-acting Insulin Glargine Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Long-acting Insulin Glargine Revenue by Type (2021-2026) & (k units) Table 25. Global Long-acting Insulin Glargine Revenue by Type (2027-2032) & (k units) Table 26. Global Long-acting Insulin Glargine Revenue Market Share by Type (2021-2026) Table 27. Global Long-acting Insulin Glargine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Type 2 Diabetes Table 29. Major Manufacturers of Type 1 Diabetes Table 30. Global Long-acting Insulin Glargine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Long-acting Insulin Glargine Sales by Application (2021-2026) & (k units) Table 32. Global Long-acting Insulin Glargine Sales by Application (2027-2032) & (k units) Table 33. Global Long-acting Insulin Glargine Sales Market Share by Application (2021-2026) Table 34. Global Long-acting Insulin Glargine Sales Market Share by Application (2027-2032) Table 35. Global Long-acting Insulin Glargine Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Long-acting Insulin Glargine Revenue by Application (2021-2026) & (k units) Table 37. Global Long-acting Insulin Glargine Revenue by Application (2027-2032) & (k units) Table 38. Global Long-acting Insulin Glargine Revenue Market Share by Application (2021-2026) Table 39. Global Long-acting Insulin Glargine Revenue Market Share by Application (2027-2032) Table 40. Global Long-acting Insulin Glargine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Long-acting Insulin Glargine Sales by Region (2021-2026) & (k units) Table 42. Global Long-acting Insulin Glargine Sales Market Share by Region (2021-2026) Table 43. Global Long-acting Insulin Glargine Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Long-acting Insulin Glargine Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Long-acting Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 47. North America Long-acting Insulin Glargine Sales by Country (2027-2032) & (k units) Table 48. Europe Long-acting Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 50. Europe Long-acting Insulin Glargine Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Long-acting Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Long-acting Insulin Glargine Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Long-acting Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Long-acting Insulin Glargine Sales by Country (2027-2032) & (k units) Table 57. Global Long-acting Insulin Glargine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Long-acting Insulin Glargine Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Long-acting Insulin Glargine Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Long-acting Insulin Glargine Revenue Market Share by Region (2021-2026) Table 61. Global Long-acting Insulin Glargine Revenue Market Share by Region (2027-2032) Table 62. Biocare Company Information Table 63. Biocare Business Overview Table 64. Biocare Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Biocare Long-acting Insulin Glargine Product Portfolio Table 66. Biocare Recent Development Table 67. Biocon Biologics Company Information Table 68. Biocon Biologics Business Overview Table 69. Biocon Biologics Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Biocon Biologics Long-acting Insulin Glargine Product Portfolio Table 71. Biocon Biologics Recent Development Table 72. Cipla Company Information Table 73. Cipla Business Overview Table 74. Cipla Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Cipla Long-acting Insulin Glargine Product Portfolio Table 76. Cipla Recent Development Table 77. INFION PHARMA Company Information Table 78. INFION PHARMA Business Overview Table 79. INFION PHARMA Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. INFION PHARMA Long-acting Insulin Glargine Product Portfolio Table 81. INFION PHARMA Recent Development Table 82. KALBE PHARMA Company Information Table 83. KALBE PHARMA Business Overview Table 84. KALBE PHARMA Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. KALBE PHARMA Long-acting Insulin Glargine Product Portfolio Table 86. KALBE PHARMA Recent Development Table 87. Lupin Laboratories Company Information Table 88. Lupin Laboratories Business Overview Table 89. Lupin Laboratories Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Lupin Laboratories Long-acting Insulin Glargine Product Portfolio Table 91. Lupin Laboratories Recent Development Table 92. Swixx Biopharma Company Information Table 93. Swixx Biopharma Business Overview Table 94. Swixx Biopharma Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Swixx Biopharma Long-acting Insulin Glargine Product Portfolio Table 96. Swixx Biopharma Recent Development Table 97. Viatris Company Information Table 98. Viatris Business Overview Table 99. Viatris Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Viatris Long-acting Insulin Glargine Product Portfolio Table 101. Viatris Recent Development Table 102. Wockhardt Company Information Table 103. Wockhardt Business Overview Table 104. Wockhardt Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Wockhardt Long-acting Insulin Glargine Product Portfolio Table 106. Wockhardt Recent Development Table 107. Gan & Lee Company Information Table 108. Gan & Lee Business Overview Table 109. Gan & Lee Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Gan & Lee Long-acting Insulin Glargine Product Portfolio Table 111. Gan & Lee Recent Development Table 112. Eli Lilly & Co Company Information Table 113. Eli Lilly & Co Business Overview Table 114. Eli Lilly & Co Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Eli Lilly & Co Long-acting Insulin Glargine Product Portfolio Table 116. Eli Lilly & Co Recent Development Table 117. Sanofi Company Information Table 118. Sanofi Business Overview Table 119. Sanofi Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Sanofi Long-acting Insulin Glargine Product Portfolio Table 121. Sanofi Recent Development Table 122. Tonghua Dongbao Company Information Table 123. Tonghua Dongbao Business Overview Table 124. Tonghua Dongbao Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Tonghua Dongbao Long-acting Insulin Glargine Product Portfolio Table 126. Tonghua Dongbao Recent Development Table 127. United Laboratories Company Information Table 128. United Laboratories Business Overview Table 129. United Laboratories Long-acting Insulin Glargine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. United Laboratories Long-acting Insulin Glargine Product Portfolio Table 131. United Laboratories Recent Development Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Long-acting Insulin Glargine Distributors List Table 135. Long-acting Insulin Glargine Customers List Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Long-acting Insulin Glargine Product Image Figure 2. Global Long-acting Insulin Glargine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Insulin Glargine Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting Insulin Glargine Sales (2021-2032) & (k units) Figure 5. Global Long-acting Insulin Glargine Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Long-acting Insulin Glargine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Vial Image Figure 9. Prefilled Image Figure 10. Global Long-acting Insulin Glargine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Long-acting Insulin Glargine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Long-acting Insulin Glargine Sales Market Share by Type (2021-2032) Figure 13. Global Long-acting Insulin Glargine Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Long-acting Insulin Glargine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Long-acting Insulin Glargine Revenue Market Share by Type (2021-2032) Figure 16. Type 2 Diabetes Image Figure 17. Type 1 Diabetes Image Figure 18. Global Long-acting Insulin Glargine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Long-acting Insulin Glargine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Long-acting Insulin Glargine Sales Market Share by Application (2021-2032) Figure 21. Global Long-acting Insulin Glargine Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Long-acting Insulin Glargine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Long-acting Insulin Glargine Revenue Market Share by Application (2021-2032) Figure 24. North America Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Long-acting Insulin Glargine Sales Market Share by Country (2021-2032) Figure 26. U.S. Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Long-acting Insulin Glargine Sales Market Share by Country (2021-2032) Figure 31. Germany Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Long-acting Insulin Glargine Sales Market Share by Country (2021-2032) Figure 38. China Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Long-acting Insulin Glargine Sales Market Share by Country (2021-2032) Figure 46. Brazil Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Long-acting Insulin Glargine Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Long-acting Insulin Glargine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Long-acting Insulin Glargine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Figure 57. North America Long-acting Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Figure 59. Europe Long-acting Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Long-acting Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Long-acting Insulin Glargine Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Long-acting Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Long-acting Insulin Glargine Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Long-acting Insulin Glargine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Vial
  • Prefilled
Applications
  • Type 2 Diabetes
  • Type 1 Diabetes
Companies covered
  • Biocare
  • Biocon Biologics
  • Cipla
  • INFION PHARMA
  • KALBE PHARMA
  • Lupin Laboratories
  • Swixx Biopharma
  • Viatris
  • Wockhardt
  • Gan & Lee
  • Eli Lilly & Co
  • Sanofi
  • Tonghua Dongbao
  • United Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-acting Insulin Glargine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-acting Insulin Glargine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Long-acting Insulin Glargine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Long-acting Insulin Glargine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Long-acting Insulin Glargine Market Dynamics
  1. 2.1 Long-acting Insulin Glargine Industry Trends
  2. 2.2 Long-acting Insulin Glargine Industry Drivers
  3. 2.3 Long-acting Insulin Glargine Industry Opportunities and Challenges
  4. 2.4 Long-acting Insulin Glargine Industry Restraints
3 Long-acting Insulin Glargine Market by Manufacturers
  1. 3.1 Global Long-acting Insulin Glargine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Long-acting Insulin Glargine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Long-acting Insulin Glargine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Long-acting Insulin Glargine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting Insulin Glargine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Long-acting Insulin Glargine Manufacturers, Product Type & Application
  7. 3.7 Global Long-acting Insulin Glargine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting Insulin Glargine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting Insulin Glargine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting Insulin Glargine Tier 1, Tier 2, and Tier 3
4 Long-acting Insulin Glargine Market by Type
  1. 4.1 Long-acting Insulin Glargine Type Introduction
  2. 4.1.1 Vial
  3. 4.1.2 Prefilled
  4. 4.2 Global Long-acting Insulin Glargine Sales by Type
  5. 4.2.1 Global Long-acting Insulin Glargine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Long-acting Insulin Glargine Sales by Type (2021-2032)
  7. 4.2.3 Global Long-acting Insulin Glargine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Long-acting Insulin Glargine Revenue by Type
  9. 4.3.1 Global Long-acting Insulin Glargine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Long-acting Insulin Glargine Revenue by Type (2021-2032)
  11. 4.3.3 Global Long-acting Insulin Glargine Revenue Market Share by Type (2021-2032)
5 Long-acting Insulin Glargine Market by Application
  1. 5.1 Long-acting Insulin Glargine Application Introduction
  2. 5.1.1 Type 2 Diabetes
  3. 5.1.2 Type 1 Diabetes
  4. 5.2 Global Long-acting Insulin Glargine Sales by Application
  5. 5.2.1 Global Long-acting Insulin Glargine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Long-acting Insulin Glargine Sales by Application (2021-2032)
  7. 5.2.3 Global Long-acting Insulin Glargine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Long-acting Insulin Glargine Revenue by Application
  9. 5.3.1 Global Long-acting Insulin Glargine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Long-acting Insulin Glargine Revenue by Application (2021-2032)
  11. 5.3.3 Global Long-acting Insulin Glargine Revenue Market Share by Application (2021-2032)
6 Global Long-acting Insulin Glargine Sales by Region
  1. 6.1 Global Long-acting Insulin Glargine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Insulin Glargine Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Insulin Glargine Sales by Region (2021-2026)
  4. 6.2.2 Global Long-acting Insulin Glargine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-acting Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Long-acting Insulin Glargine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Long-acting Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Long-acting Insulin Glargine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Long-acting Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Long-acting Insulin Glargine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Long-acting Insulin Glargine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Long-acting Insulin Glargine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Long-acting Insulin Glargine Revenue by Region
  1. 7.1 Global Long-acting Insulin Glargine Revenue by Region
  2. 7.1.1 Global Long-acting Insulin Glargine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Long-acting Insulin Glargine Revenue by Region (2021-2026)
  4. 7.1.3 Global Long-acting Insulin Glargine Revenue by Region (2027-2032)
  5. 7.1.4 Global Long-acting Insulin Glargine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Long-acting Insulin Glargine Revenue (2021-2032)
  8. 7.2.2 North America Long-acting Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Long-acting Insulin Glargine Revenue (2021-2032)
  11. 7.3.2 Europe Long-acting Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Long-acting Insulin Glargine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Long-acting Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Long-acting Insulin Glargine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Long-acting Insulin Glargine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Biocare
  2. 8.1.1 Biocare Company Information
  3. 8.1.2 Biocare Business Overview
  4. 8.1.3 Biocare Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biocare Long-acting Insulin Glargine Product Portfolio
  6. 8.1.5 Biocare Recent Developments
  7. 8.2 Biocon Biologics
  8. 8.2.1 Biocon Biologics Company Information
  9. 8.2.2 Biocon Biologics Business Overview
  10. 8.2.3 Biocon Biologics Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biocon Biologics Long-acting Insulin Glargine Product Portfolio
  12. 8.2.5 Biocon Biologics Recent Developments
  13. 8.3 Cipla
  14. 8.3.1 Cipla Company Information
  15. 8.3.2 Cipla Business Overview
  16. 8.3.3 Cipla Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cipla Long-acting Insulin Glargine Product Portfolio
  18. 8.3.5 Cipla Recent Developments
  19. 8.4 INFION PHARMA
  20. 8.4.1 INFION PHARMA Company Information
  21. 8.4.2 INFION PHARMA Business Overview
  22. 8.4.3 INFION PHARMA Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 INFION PHARMA Long-acting Insulin Glargine Product Portfolio
  24. 8.4.5 INFION PHARMA Recent Developments
  25. 8.5 KALBE PHARMA
  26. 8.5.1 KALBE PHARMA Company Information
  27. 8.5.2 KALBE PHARMA Business Overview
  28. 8.5.3 KALBE PHARMA Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 KALBE PHARMA Long-acting Insulin Glargine Product Portfolio
  30. 8.5.5 KALBE PHARMA Recent Developments
  31. 8.6 Lupin Laboratories
  32. 8.6.1 Lupin Laboratories Company Information
  33. 8.6.2 Lupin Laboratories Business Overview
  34. 8.6.3 Lupin Laboratories Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lupin Laboratories Long-acting Insulin Glargine Product Portfolio
  36. 8.6.5 Lupin Laboratories Recent Developments
  37. 8.7 Swixx Biopharma
  38. 8.7.1 Swixx Biopharma Company Information
  39. 8.7.2 Swixx Biopharma Business Overview
  40. 8.7.3 Swixx Biopharma Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Swixx Biopharma Long-acting Insulin Glargine Product Portfolio
  42. 8.7.5 Swixx Biopharma Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Long-acting Insulin Glargine Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Wockhardt
  50. 8.9.1 Wockhardt Company Information
  51. 8.9.2 Wockhardt Business Overview
  52. 8.9.3 Wockhardt Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Wockhardt Long-acting Insulin Glargine Product Portfolio
  54. 8.9.5 Wockhardt Recent Developments
  55. 8.10 Gan & Lee
  56. 8.10.1 Gan & Lee Company Information
  57. 8.10.2 Gan & Lee Business Overview
  58. 8.10.3 Gan & Lee Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Gan & Lee Long-acting Insulin Glargine Product Portfolio
  60. 8.10.5 Gan & Lee Recent Developments
  61. 8.11 Eli Lilly & Co
  62. 8.11.1 Eli Lilly & Co Company Information
  63. 8.11.2 Eli Lilly & Co Business Overview
  64. 8.11.3 Eli Lilly & Co Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Eli Lilly & Co Long-acting Insulin Glargine Product Portfolio
  66. 8.11.5 Eli Lilly & Co Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Long-acting Insulin Glargine Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Tonghua Dongbao
  74. 8.13.1 Tonghua Dongbao Company Information
  75. 8.13.2 Tonghua Dongbao Business Overview
  76. 8.13.3 Tonghua Dongbao Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Tonghua Dongbao Long-acting Insulin Glargine Product Portfolio
  78. 8.13.5 Tonghua Dongbao Recent Developments
  79. 8.14 United Laboratories
  80. 8.14.1 United Laboratories Company Information
  81. 8.14.2 United Laboratories Business Overview
  82. 8.14.3 United Laboratories Long-acting Insulin Glargine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 United Laboratories Long-acting Insulin Glargine Product Portfolio
  84. 8.14.5 United Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Insulin Glargine Value Chain Analysis
  2. 9.1.1 Long-acting Insulin Glargine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Insulin Glargine Production Mode & Process
  6. 9.2 Long-acting Insulin Glargine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Insulin Glargine Distributors
  9. 9.2.3 Long-acting Insulin Glargine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst